Emmaus Life Sciences, Inc. 8-K

What Happened
On May 15, 2026, Emmaus Life Sciences, Inc. filed a Form 8-K (Item 2.02) announcing its results of operations and financial condition for the three months ended March 31, 2026. The company issued a press release with those quarterly results; the press release is included as Exhibit 99.1 to the Current Report and is incorporated by reference.

Key Details

• Filing date: May 15, 2026; reporting period: three months ended March 31, 2026.
• Disclosure made under Item 2.02 (Results of Operations and Financial Condition).
• Press release containing the quarterly results is attached as Exhibit 99.1 to the 8‑K.
• The 8‑K did not report other material events (e.g., executive changes or transactions) beyond the results disclosure.

Why It Matters
This Form 8‑K delivers Emmaus’s latest quarterly results to investors and the market. Retail investors should read the attached press release (Exhibit 99.1) for the specific revenue, earnings, cash position and management commentary to assess the company’s recent performance and any implications for the stock.